Biguanides are longstanding pharmaco thera peutics agents against diabetes mellitus. In early medieval times, Galega officinalis (also known as French lilac or goat'srue) was used as a remedy for diabetes mellitus, and in the 1920s guani dino compounds were identified in French lilac extracts 1 . Oral biguanide agents became available for the treatment of dia betes mellitus in the 1950s, and metformin was approved as an antidiabetic drug by the FDA in 1995. Since then, metformin has had demon strated efficacy in improving multiple meta bolic end points, including insulin sensitivity, the metabolism of free fatty acids, dyslipid aemia, excess body fat and weight, and cardio vascular health. In a corollary study of the UK Prospective Diabetes Study, in which 1,704 overweight patients with diabetes mellitus were randomly assigned to receive conventional ver sus intensive therapy with metformin, insulin or the antidiabetic agents chlorpropamide or glibenclamide, those given metformin had a lower risk of myocardial infarction, all dia betes end points, diabetesrelated death and all cause mortality than patients in other groups 2 . Thus, the American Diabetes Association and European Association for the Study of Diabetes recommend that metformin treatment is initi ated when diabetes mellitus is diagnosed, bar ring no contraindications 3 . However, debate remains regarding the safety of metformin in the setting of impaired kidney function due to the risk of metformin associated lactic acidosis (MALA). Two studies now examine metformin and the complications of acute Tayside (GoDARTs) cohort, cases of lactic acidosis were defined as those with lactate >5 mmol/l and serum bicarbonate <18 mmol/l; controls were defined as those in the remain ing source population with normal lactate levels; metformin users were defined as indi viduals who recieved a metformin prescription within 3 months prior to lactate measure ment. Using mixed effects logistic regression models, the investigators observed a 2.3fold higher risk of lactic acidosis among metformin users versus nonusers. The presence of AKI (as judged using serum creatinine criteria from the Kidney Disease: Improving Global Outcomes (KDIGO) guidelines) modified the metformin-lactic acidosis relationship; the association between these parameters increased with increased AKI severity. In the overall cohort, lactate concentrations were 0.34 mmol/l higher in metformin users versus nonusers; a greater increase in lactate concen tration was observed with increasing severity of AKI.
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Bell et al. examined the interaction between metformin, AKI, and adverse outcomes in another cohort based in Tayside, Scotland 4 . By linking Health Informatics Centre elec tronic health record data from a population of ~400,000 residents in Tayside to the Scottish Care InitiativeDiabetes Collaboration (which includes records for 99% of patients with diabetes mellitus in Scotland), and to a pre scription database of all community phar macies in Tayside, the investigators identified 25,148 patients with type 2 diabetes mellitus for whom prescription data between 2004 and 2013 was available. They examined the association between metformin and the risk of hospitalbased AKI, which was defined by creatininebased KDIGO criteria, with the aim of using AKI as a proxy of lactic acidosis. Using timeupdated medication data, they did not find an association between metformin and AKI. However, patients that had 'ever' used metformin had a 1.3fold higher risk of AKI than those who had 'never' used metformin. Yet inference from these findings is limited by the fact that AKI is not a specific proxy for lactic acidosis, and by the lack of biochemical data confirming the presence of MALA. The investigators also found that metformin use versus no treatment at admission in patients with incident AKI was associated with a greater 28day survival. Finally, the baseline kidney kidney injury (AKI) and lactic acidosis in two wellcharacterized cohorts of patients with diabetes mellitus 4, 5 . In the 1970s, phenformin and buformin (antidiabetic drugs of the biguanide class) were withdrawn from the market in most countries due to complications of lifethreatening lac tic acidosis 1 . Although the frequency of lactic acid osis due to metformin is comparatively lower than that of phenformin, metformin use is restricted in kidney disease given the risk of MALA. In individuals with normal kidney function, metformin is filtered from the glo merulus and secreted from the proximal tubule in a nonmetabolized and nonprotein bound form, but its clearance decreases by 75% when estimated glomerular filtration (eGFR) falls to 30-59 ml/min/1.73 m 2 (REF. 6 ). The accumula tion of metformin and the associated toxicity impairs mitochondrial function and oxygen consumption and diminishes gluconeogene sis and glycogenolysis, leading to the genera tion of lactate and a nonhypoxic type B lactic acid osis 1 . Whereas AKI is a key precipitant of MALA in patients on stable metformin ther apy, sparse epidemiologic data exists on the interrelationships between metformin use, AKI and lactic acidosis.
To address this gap in knowledge, Connelly et al. conducted a casecontrol study of 1,746 participants with type 2 diabetes mellitus and 846 individuals without diabetes, all of whom underwent lactate measurement between 1994 and 2014 in Tayside, Scotland 5 
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Connie M. Rhee and Kamyar Kalantar-Zadeh
Debate exists regarding the safety of metformin and the risk of metforminassociated lactic acidosis, particularly in the setting of kidney dysfunction. Data from two studies examining the interplay between metformin, acute kidney injury, and complications including lactic acidosis suggest that metformin should be used conservatively in patients with kidney dysfunction. function of patients predicted hospitalbased AKI because incrementally higher rates of AKI were observed with increasingly lower eGFRs.
These two reports are timely, given recent policylevel changes in metformin regulation. The US FDA has relaxed its rec ommendations to allow metformin use in patients with mild and moderate kidney dysfunction (eGFR 45-59 ml/min/1.73 m 2 and 30-44 ml/min/1.73 m 2 , respectively) 6 , and European Medicines Agency guidelines have been eased to allow metformin use in moderate kidney dysfunction (eGFR 30-59 ml/min/1.73 m 2 ) 4 . Although the met formin package insert advises against its use in conditions leading to AKI (including cardiovas cular collapse or shock, myocardial infarction and sepsis), the FDA does not recommend with holding metformin in this context 6 . However, the UK Renal Association and National Health Services England advocate that metformin be discontinued in AKIpredisposing illnesses 5 . Several findings from the studies discussed suggest that metformin should be more conservatively used in patients with kidney dysfunction. First, Connelly et al. present compelling data indicating that metformin should be discontinued in AKIpredisposing conditions given the heightened risk of MALA. Although Bell et al. showed that met formin use was associated with comparatively greater survival among incident AKI cases, the absence of a 'newuser' design may not have accounted for patients who stopped using met formin or died due to its adverse effects before study entry, biasing results towards a protec tive effect. Second, as Bell et al. demonstrated that underlying kidney dysfunction is a major predictor of AKI, metformin should be pre scribed with caution to patients with chronic kidney disease (CKD). Third, although both studies add knowledge to the field, they also highlight the challenges of accurately identi fying MALA by epidemiologic studies alone. For example, Connelly et al. observed a higher crude incidence rate of lactic acidosis as com pared with other recent studies, possibly due to selection bias as nonprotocolized lactate measurements were obtained from clinical data whereby metformin users may have undergone more frequent testing. Conversely, although systematic reviews suggest that MALA inci dence is low, this low incidence may be due to the underrepresentation of highrisk popula tions in these studies (TABLE 1) , nonsensitive and nonspecific methods of outcome ascer tainment (diagnostic codes) and residual con founding by nonindication. Rigorous studies, including clinical trials that examine the safety and effectiveness of metformin in CKD and/or other highrisk groups, should determine the eGFR threshold above which metformin use is safe. Meanwhile, we recommend reviewing the use of metformin in patients with eGFR 45-59 ml/min/1.73 m 2 , discontinuing its use when eGFR is <45 ml/min/1.73 m 2 , and discon tinuing metformin in other AKIpredisposing conditions irrespective of eGFR
